Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Orthocell Limited (OCC.AX)
Murdoch, WA, AU
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
Based on only 1 article — low confidence
- Microsoft axes 2% of workforce as 'AI is changing how work gets done' Proactive Investors - Finance
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.29% | -6.71% | -14.53% | -19.47% | -28.50% | -29.82% | -39.76% | +109.59% | +40.37% | +98.70% | +91.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+42.1% ★ Q4'25: +111.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-8.2% Q4'25: +19.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-170.9% Q4'25: -167.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-185.1% Q4'25: -162.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +1,486.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+10.5% Q4'25: +24.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q4'25: -0.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 1 EPS Ana. |
Jun 2027 2 Rev. Ana. 1 EPS Ana. |
Jun 2028 2 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. |
Jun 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
4.24M
est: 3.40M (+24.8%)
|
5.32M
est: 6.72M (-20.9%)
|
7.55M
est: 9.19M (-17.8%)
|
12.83M
11.86M – 13.80M
+39.6% YoY
|
22.80M
21.49M – 24.11M
+77.7% YoY
|
40.67M
38.68M – 42.66M
+78.4% YoY
|
68.70M
64.32M – 73.08M
+68.9% YoY
|
101.10M
94.66M – 107.54M
+47.2% YoY
|
| EBITDA |
-10.34M
est: -3.40M (-204.1%)
|
-11.68M
est: -6.72M (-73.8%)
|
-13.43M
est: -9.19M (-46.1%)
|
-12.83M
-13.80M – -11.86M
-39.6% YoY
|
-22.80M
-24.11M – -21.49M
-77.7% YoY
|
-40.67M
-42.66M – -38.68M
-78.4% YoY
|
-68.70M
-73.08M – -64.32M
-68.9% YoY
|
-101.10M
-107.54M – -94.66M
-47.2% YoY
|
| EBIT |
-10.89M
est: -3.40M (-220.4%)
|
-12.20M
est: -6.72M (-81.5%)
|
-13.98M
est: -9.19M (-52.1%)
|
-12.83M
-13.80M – -11.86M
-39.6% YoY
|
-22.80M
-24.11M – -21.49M
-77.7% YoY
|
-40.67M
-42.66M – -38.68M
-78.4% YoY
|
-68.70M
-73.08M – -64.32M
-68.9% YoY
|
-101.10M
-107.54M – -94.66M
-47.2% YoY
|
| Net Income |
-6.25M
est: -7.77M (+19.6%)
|
-7.18M
est: -7.37M (+2.5%)
|
-8.57M
est: -5.36M (-59.9%)
|
-9.08M
-9.19M – -8.97M
-69.4% YoY
|
-6.18M
-7.31M – -5.04M
+32.0% YoY
|
-744.1K
-805.8K – -682.5K
+88.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
5.96M
est: 8.27M (-27.9%)
|
6.70M
est: 16.35M (-59.0%)
|
9.41M
est: 22.35M (-57.9%)
|
31.22M
28.85M – 33.58M
+39.6% YoY
|
55.46M
52.28M – 58.64M
+77.7% YoY
|
98.92M
94.07M – 103.76M
+78.4% YoY
|
167.11M
156.46M – 177.75M
+68.9% YoY
|
245.92M
230.25M – 261.58M
+47.2% YoY
|
| EPS |
-0.03
est: -0.03 (+8.9%)
|
-0.04
est: -0.03 (-7.6%)
|
-0.04
est: -0.02 (-60.0%)
|
-0.04
-0.04 – -0.04
-69.4% YoY
|
-0.03
-0.03 – -0.02
+32.0% YoY
|
0.00
0.00 – 0.00
+88.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.03% | 192.0K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul Frederick Anderson | Chief Executive Officer, MD & Executive Director | 633.2K | male |
| Alex McHenry | Chief Operating Officer | — | male |
| Jim Piper | Chief Financial Officer | — | male |
| John Walker | Vice President of Sales | — | — |
| Kevin Leach | Head of Marketing | — | male |
| Ming Hao Zheng | Chief Scientific Officer and Member of Medical & Scientific Advisory Board | — | — |
| Peter Gordon Webse FCIS FCPA FGIA | Company Secretary | — | male |
| Adam Wood | Chief Commercial Officer | — | male |
| Tony Macintyre | Chief Technical Operations Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OCC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
